Esperion Therapeutics, Inc. (ESPR)
| Previous close | 1.0900 |
| Open | 1.0800 |
| Bid | 0.9508 x 900 |
| Ask | 0.9550 x 2200 |
| Day's range | 0.9255 - 1.0999 |
| 52-week range | 0.9255 - 8.8700 |
| Volume | |
| Avg. volume | 3,398,109 |
| Market cap | 101.334M |
| Beta (5Y monthly) | 0.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4300 |
| Earnings date | 30 Oct 2023 - 03 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.13 |
GlobeNewswireAmerican College of Cardiology Program to Increase Cholesterol Screenings
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, “Driving Urgency in LDL Screening,” to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular d
ZacksWhy Is Esperion Therapeutics (ESPR) Down 10.6% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a corporate presentation on Monday, September 11, 2023 at 3:00 PM ET. The Esperion management team will also host investor meetings that same day. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investo
